| GOSERELIN ACETATE
Classifications: hormone; gonadotropin-releasing hormone (gnrh) analog; Therapeutic: gnrh analog
Pregnancy Category: X
3.6 mg, 10.8 mg SC implant
A synthetic form of luteinizing hormone-releasing hormone (LHRH or GnRH) that inhibits pituitary gonadotropin secretion.
With chronic administration, serum testosterone levels fall into the range normally seen with surgically castrated men.
Prostate cancer, breast cancer. Endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
Endometriosis, uterine leiomyomas.
Known hypersensitivity to an LHRH; vaginal bleeding; endometriosis or endometrial thinning; hypercalcemia; pregnancy (category
Urinary tract obstruction and children; family history of osteoporosis; concurrent use with anticonvulsants or corticosteroids;
osteoporosis; patients at risk for spinal cord compression or urinary tract obstruction. Safety and efficacy in children
are not established.
Route & Dosage
|Prostate Cancer, Breast Cancer, Endometriosis, Uterine Leiomyomas
Adult: SC 3.6 mg once q28d, 10.8 mg depot q12wk
Endometrial Thinning Prior to Endometrial Ablation
Adult: SC 3.6 mg once q28d
- Follow manufacturer's directions exactly for implanting the drug SC in the upper abdominal wall.
- Store at room temperature not to exceed 25° C (77° F).
Adverse Effects (≥1%)CNS:
Headache, tumor flare. Endocrine:
Gynecomastia, breast swelling and tenderness, postmenopausal symptoms
vaginal dryness). GI:
Vaginal spotting, breakthrough bleeding, decreased libido, impotence. Musculoskeletal:
Bone pain, bone loss.
Diagnostic Test Interference
Increased levels of alkaline phosphatase and estradiol in the first 18 d; initial increase then decrease in FSH, LH, and testosterone.
No clinically significant interactions established.
Rapidly absorbed following SC administration
29 d. Elimination:
Excreted by kidneys. Half-Life:
Assessment & Drug Effects
- Monitor carefully during the first month of therapy for S&S of spinal cord compression or ureteral obstruction in patients
with prostate cancer. Report immediately to physician.
- Anticipate a transient worsening of symptoms (e.g., bone pain) during the first weeks of therapy in patients with prostate
Patient & Family Education
- Note: Sexual dysfunction in men and hot flashes may accompany drug use.
- Notify physician immediately of symptoms of spinal cord compression or urinary obstruction.